Detalhe da pesquisa
1.
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Cardiovasc Diabetol
; 19(1): 199, 2020 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33239067